Our technology platform is based solely on our proprietary drug delivery technology. Our ongoing
clinical trials for certain of our product candidates may be delayed, or fail, which will harm our business.
Our strategy is to
concentrate our product development activities primarily on pharmaceutical products for which there already are significant prescription sales, where the use of our proprietary, novel drug delivery technology could potentially enhance speed of onset
of therapeutic effect, could potentially reduce side effects through a reduction of the amount of active drug substance required to produce a given therapeutic effect and improve patient convenience or compliance.
Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials, even after obtaining
promising results in earlier trials. Data obtained from tests are susceptible to varying interpretations which may delay, limit or prevent regulatory approval. In addition, companies may be unable to enroll patients quickly enough to meet
expectations for completing clinical trials. The timing and completion of current and planned clinical trials of our product candidates depend on, among other factors, the rate at which patients are enrolled, which is a function of many factors,
including:
| |
• |
|
the number of clinical sites; |
| |
• |
|
the size of the patient population; |
| |
• |
|
the proximity of patients to the clinical sites; |
| |
• |
|
the eligibility criteria for the study; |
| |
• |
|
the existence of competing clinical trials; and |
| |
• |
|
the existence of alternative available products. |
Delays in patient enrollment in clinical trials may occur, which would likely result in increased costs, program delays or both.
Our business and revenue is dependent on the successful development of our products.
Our future growth and profitability will be dependent upon our ability to complete the development of, obtain regulatory approvals for and license out or
market our product candidates. Accordingly, our prospects must be considered in light of the risks, expenses and difficulties frequently encountered in connection with the establishment of a new business in a highly competitive industry,
characterized by frequent new product introductions. We anticipate that we will incur substantial operating expenses in connection with the development, testing and approval of our product candidates and expect these expenses to result in continuing
and significant operating losses until such time, if ever, that we are able to achieve adequate levels of sales or license revenues.
Some of our product candidates are in early stages of clinical development and some are in preclinical testing, which may affect our ability or the
time we require to obtain necessary regulatory approvals.
Some of our product candidates are in early stages of clinical development,
such as our Duromist product candidate, and some are in preclinical testing. These product candidates are continuously evaluated and assessed and are often subject to changes in formulation and technology. The regulatory requirements governing these
types of products may be less well defined or more rigorous than for conventional products. As a result, we may experience delays with our preclinical and clinical testing, and a longer and more expensive regulatory process in connection with
obtaining regulatory approvals of these types of product candidates as compared to others in our pipeline at later stages of development. These delays may negatively affect our business and operations.
We may not be able to successfully develop any one or more of our product candidates or develop such product candidates on a timely basis. Further, such
product candidates may not be commercially accepted if developed. The inability to successfully complete development, or a determination by us, for financial or other reasons, not to undertake to complete development of any product candidates,
particularly in instances in which we have made significant capital expenditures, could have a material adverse effect on our business and operations.
23
F 888.329.6696